Cardioprotection thread, page-216

@JH888 sorry for the late reply but we definitely need a dedicated resource to raise awareness in the overseas markets (US, Japan, China and EU).

Both Dr. T. and Dr. S. wear way too many hats in Race and outside of Race. Duggan & Rothbaum were full time CEOs in their biotech companies, Pharmacyclic and Acerta, respectively. Rothbaum also had a finance company but that was pretty much managed by his CEO.

Currently, we do not have a CSO, so it is most likely that Dr. T is doing this job as well as his CEO role, his private company(ies) and other investments. Dr. S on his LinkedIn profile is currently a CEO of Amala Therapeutics, which he is also the Founder, and you would think this would be his baby, eventhough he loves bisantrene. He's also an NED for 2 other companies (part time) and Exec-Director (also part time) at Race.

Race do have existing international contacts (but how many) and updating these contacts with our progress but we need to increase this contact database by many folds if we want to increase our chance of having an international bidding war for a blockbuster buyout.

It's definitely a sales game where we will be trying to flog off bisantrene to the highest bidder. But we have to prepare and do the background work now. To increase international awareness, not just in the US but also other markets like Japan, China and EU, a dedicated international business development/sales manager needs to increase the number of eyeballs on bisantrene and it's progress from H2.24 as we embark on P1 trial. The more international eyeballs on bisantrene, the higher the chance of getting an international bidding war.

There's 2 main sales and marketing strategies, Push and Pull. By having a dedicated resource, he/she can leverage of existing network, data mine for global contacts, establish and build relationships with BPs and keep on pushing the bisantrene narrative to them. It's a direct approach, reaching a targeted audience. The Pull strategy is when you cast bisantrene's narrative out there to a targeted mass audience, trying to pull interested parties in to doing more research and or make inquiries into acquiring bisantrene. Examples of Pull activities can be having a booth or presenting your results at the international medical conferences, eg. ASH, ASCO and JPM, have our cardio protective paper published in targeted reputable medical publications with a good readership/subscription/audience, eg. NEJM. We had 2 posters and pressos at previous ASH but not under the Race brand nor did we have any Race staff there waving our flag or taking questions and having discussions straight after the 2 posters were presented, which was a bit of a lost opportunity.

Race is currently doing very little of the Push strategy, definitely on a part-time basis. We are definitely not doing the Pull strategy on the global stage at the moment. The first pull strategy could be the cardio protection paper in a reputable publication when it is finished. P1 interim result could be another one in end of this year or early next year or maybe the final P1 result in 2025 ? So we won't see any Pull strategies for a long time. We need to increase our focus, intensity and urgency to increase the number of eyeballs on bisantrene, globally.

Yes we have Otsuka as a supply partner but imagine if we have Japan's Top 20 pharmas fighting to be our supply partner or some other types of partnership ? Pete's talking about a deal in China but imagine if we have the Top 20 pharmas in China keeping an eye on bisantrene and knowing that we are partners with Otsuka ? The same for the EU. What do you think the Americans and Eurpean BPs will do when the Japanese and or Chinese put a bid in for bisantrene ? Boom !